RecruitingPhase 1Phase 2NCT05374278

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in the Brains of Healthy Controls and Patients With Dementia.

Sponsor

David Wilson

Enrollment

102 participants

Start Date

Nov 2, 2021

Study Type

INTERVENTIONAL

Conditions

Dementia Alzheimer Disease Frontotemporal Dementia

Summary

This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).

Eligibility

Min Age: 40 YearsMax Age: 75 Years

Inclusion Criteria10

Age 40-75
Age-suitable BMI
Ability to provide written informed consent and willingly comply with protocol requirements or has a legal authorized representative/guardian who provides surrogate informed consent.
No apparent physical disorder.
Radial, ulnar, or brachial artery suitable for catheterization.
Non-smoker, and not taking OTC nicotine cessation - to limit peripheral metabolism events.
Devoid of CNS prescription drugs for three weeks - to limit peripheral metabolism events.
For Cohort 2B and 2C:
Must have a study partner (informant) who spends a minimum average of 5 hours per week with the participant (e.g. family member, significant other, friend, caregiver), is generally aware of the participant's daily activities, can provide information about the participant's cognitive and functional performance, and will accompany the participant in all study procedure.
Recent (within 6 mo.) MME clinical scores.

Exclusion Criteria8

Unable to provide written informed consent and unwilling to comply with protocol requirements, or does not have a legal authorized representative/guardian who can provide surrogate informed consent.
Inadequate arterial access.
Receipt of radioisotope \< 5 half-lives within \[18F\]RP-115 imaging- as to not confound any scans with radiation background for previous scanning, and unsuitable organ dosimetry thresholds from previous (\> two weeks) PET scans.
The performed \[18F\]RP-115 scan(s) must not represent \> 3 PET studies total within one year.
Contra-indication to magnetic resonance, including permanent pacemaker, implantable metallic device, etc.; or severe claustrophobia.
Participants who are pregnant (female patients of childbearing age will be tested prior to injection of tracer- positive test excludes from the study)
Participants who are breast-feeding.
Have a medical condition or other circumstances that in the opinion of the project physicians would significantly decrease chances of obtaining reliable data, achieving the study objective or completing the study.

Interventions

DRUG[18F]RP-115 PET/MRI or PET/CT and MRI

An I.V. bolus injection of up to 10 millicurie (mCi) \[18F\]RP-115 will be administered, followed by a PET/MRI scan or by a combination of PET/CT and MRI